Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems
- PMID: 20085389
- DOI: 10.2165/11530820-000000000-00000
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems
Abstract
As tensions between payers, responsible for ensuring prudent and principled use of scarce resources, and both providers and patients, who legitimately want access to technologies from which they could benefit, continue to mount, interest in approaches to managing the uncertainty surrounding the introduction of new health technologies has heightened. The purpose of this project was to compile an inventory of various types of 'access with evidence development' (AED) schemes, examining characteristics of the technologies to which they have been applied, the uncertainty they sought to address, the terms of arrangements of each scheme, and the policy outcomes. It also aimed to identify issues related to such schemes, including advantages and disadvantages from the perspectives of various stakeholder groups. A comprehensive search, review and appraisal of peer-reviewed and 'grey' literature were performed, followed by a facilitated workshop of academics and decision makers with expertise in AED schemes. Information was extracted and compiled in tabular form to identify patterns or trends. To enhance the validity of interpretations made, member checking was performed. Although the concept of AED is not new, evaluative data are sparse. Despite varying opinions on the 'right' answers to some of the questions raised, there appears to be consensus on a 'way forward'--development of methodological guidelines. All stakeholders seemed to share the view that AEDs offer the potential to facilitate patient access to promising new technologies and encourage innovation while ensuring effective use of scarce healthcare resources. There is no agreement on what constitutes 'sufficient evidence', and it depends on the specific uncertainty in question. There is agreement on the need for 'best practice' guidelines around the implementation and evaluation of AED schemes. This is the first attempt at a comprehensive analysis of methods that have been used to address uncertainty concerning a new drug or other technology. The analysis reveals that, although various approaches have been experimented with, many of them have not achieved the ostensible goal of the approach. This article outlines challenges related to AED schemes and issues that remain unresolved.
Similar articles
-
Access with evidence development schemes: a framework for description and evaluation.Pharmacoeconomics. 2010;28(2):143-52. doi: 10.2165/11530850-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085390
-
Access with evidence development in the UK: past experience, current initiatives and future potential.Pharmacoeconomics. 2010;28(2):163-70. doi: 10.2165/11531410-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085392
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification.Pharmacoeconomics. 2025 Jan;43(1):5-29. doi: 10.1007/s40273-024-01435-2. Epub 2024 Oct 15. Pharmacoeconomics. 2025. PMID: 39405025 Free PMC article.
-
Health technology funding decision-making processes around the world: the same, yet different.Pharmacoeconomics. 2011 Jun;29(6):475-95. doi: 10.2165/11586420-000000000-00000. Pharmacoeconomics. 2011. PMID: 21568357 Review.
Cited by
-
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.Pharmacoeconomics. 2015 Sep;33(9):905-24. doi: 10.1007/s40273-015-0293-8. Pharmacoeconomics. 2015. PMID: 26048353 Review.
-
Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer.Pharmacoeconomics. 2016 Oct;34(10):1039-50. doi: 10.1007/s40273-016-0411-2. Pharmacoeconomics. 2016. PMID: 27207252
-
Comparative effectiveness research: the view from a pharmaceutical company.Pharmacoeconomics. 2010;28(10):915-22. doi: 10.2165/11535400-000000000-00000. Pharmacoeconomics. 2010. PMID: 20831299
-
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.Clinicoecon Outcomes Res. 2011;3:117-86. doi: 10.2147/CEOR.S14407. Epub 2011 Aug 30. Clinicoecon Outcomes Res. 2011. PMID: 22046102 Free PMC article.
-
The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.Front Pharmacol. 2021 Aug 10;12:699466. doi: 10.3389/fphar.2021.699466. eCollection 2021. Front Pharmacol. 2021. PMID: 34456724 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials